Astellas adds senior executives to global development team
pharmafile | May 4, 2011 | Appointment | Research and Development |Â Â appointment, research and developmentÂ
Astellas Pharma has made four new senior appointments to its US-based global development team.
Former Eli Lilly vice president of translational medicine & pharmacogenomics Stephen Eck joins as vice president, head of medical oncology. He has more than 28 years of pharma experience focused primarily in oncology research.
Karen Reeves, who previously served as a vice president at Pfizer, is appointed vice president, global head of medical science at Astellas. She has more than 16 years of experience in phase I – IV drug development across multiple therapeutic areas, including neuroscience, oncology, and infectious diseases.
Mark Weinberg, who will be Astellas’ therapeutic area head for CNS and pain, has more than 12 years pharma experience, most recently at Lundbeck where he focused on CNS.
Finally, Astellas has appointed Bernhardt Zeiher as vice president, therapeutic area leader of inflammation, immunology and infectious diseases. He comes to the company with more than 13 years of experience in the industry, most recently at Pfizer. where he was vice president of the inflammation/immunology therapeutic area.
“We are proud to have these outstanding professionals on the Astellas team,” said Dr. Steven Ryder, president of Astellas Pharma Global Development (APGD). “Their shared experience will add tremendous value to the company and will help accelerate APGD’s goal of introducing innovative and valuable new medical treatments.”
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
